Key facts
- J3 Bioscience’s last known valuation is $14.0M (Nov 2022).
- It has raised $6.7M across 7 recorded rounds; the latest was Seed Round ($317K) in Mar 2022.
- Notable investors include Intuitive Funding, Salt Lake Life Science Angels, TCA Venture Group, University of Utah.
- J3 Bioscience has filed 17 Form Ds with the SEC since 2015, most recently Jun 2025 ($1.0M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for J3 Bioscience
Funding rounds
7 roundsAbout J3 Bioscience
Developer of an OTC (over-the-counter) medical device designed to help improve female reproductive health. The company's device is an intravaginal ring that is intended as a long-lasting vaginal lubricating moisturizer and provides a method to enhance the ease and comfort of sexual activity and supplement the body's natural lubrication that continuously delivers moisture and contains no hormones or drugs, enabling women to maintain vaginal health.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2007
- Employees
- 5
- Website
- j3bio.com/
- Ownership
- Privately Held (backing)
J3 Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in J3 Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on J3 Bioscience in its N-PORT filings yet. We sweep new filings monthly.